More evidence that ohm20 is way ahead of the rest

More evidence that ohm20 is way ahead of the rest of us?

I may have missed an update, as I have missed some of blafarm’s updates (Thank you both!).


Great reminders not to despair when regulatory processes do not proceed at the pace we desire:


This was the July list:

updated 7-17-2020)

An incomplete list of potential treatment targets for leronlimab.

Acute Respiratory Distress Syndrome
Allergies (anaphylactic shock)
Alopecia Areata
Alzheimer's
Amyotrophic Lateral Sclerosis
Anthrax
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Castleman Disease
Coeliac Disease
Chronic Fatigue Syndrome
Chronic Kidney Disease (underlying pathologies)
COPD
COVID-19 (and other coronaviruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy (possibly other muscular dystrophies also)
Emphysema
Endometriosis
Fibromyalgia
Gout
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lupus
Lyme Disease
Marshall’s syndrome (PFAPA)
Miller Fisher Syndrome
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Osteomyelitis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Pulmonary Arterial Hypertension
Pulmonary Fibrosis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sepsis
Sickle Cell Disease (anti-inflammatory and anti-hypercoagulability effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis